A pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsis
AuthorCross, Alan S
Opal, Steven M
Palardy, John E
Baliban, Scott M
Scott, Alison J
Chahin, Abdullah B
Ernst, Robert K
PublisherSAGE Publications Inc.
MetadataShow full item record
AbstractDespite the dramatic increase in antimicrobial resistance, there is a dearth of antibiotics in development and few pharmaceutical companies working in the field. Further, any new antibiotics are likely to have a short shelf life. Ab-based interventions offer alternatives that are not likely to be circumvented by the widely prevalent antibiotic resistance genes. Bovine colostrum (BC)-the first milk after parturition, rich in nutrients and immune components-promotes gut integrity and modulates the gut microbiome. We developed a hyperimmune BC (HBC) enriched in Abs to a highly conserved LOS core region of Gram-negative bacteria by immunizing pregnant cows with a vaccine comprised of detoxified LOS from Escherichia coli O111 Rc (J5) mutant non-covalently complexed to group B meningococcal outer membrane protein (J5dLOS/OMP). This vaccine generated robust levels of anti-J5 LOS Ab in the colostrum. When given orally to neutropenic rats challenged orally with Pseudomonas aeruginosa, administration of HBC improved survival compared to non-immune rats, while both BC preparations improved survival compared to PBS controls. Elevated circulating endotoxin levels correlated with mortality. HBC and to a lesser extent non-immune BC reduced bacterial burden from the liver, lung, and spleen. We conclude that HBC and to a lesser extent BC may be effective supplements that improve outcome from lethal gut-derived disseminated infection and may reduce transmission of Gram-negative bacilli from the gastrointestinal tract.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15542
- Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum.
- Authors: Cross AS, Karreman HJ, Zhang L, Rosenberg Z, Opal SM, Lees A
- Issue date: 2014 Oct 21
- Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.
- Authors: Cross AS, Opal SM, Warren HS, Palardy JE, Glaser K, Parejo NA, Bhattacharjee AK
- Issue date: 2001 Apr 1
- Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.
- Authors: Cross AS, Opal S, Cook P, Drabick J, Bhattacharjee A
- Issue date: 2004 Feb 17
- Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.
- Authors: Cross AS, Greenberg N, Billington M, Zhang L, DeFilippi C, May RC, Bajwa KK
- Issue date: 2015 Nov 27
- Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
- Authors: Opal SM, Palardy JE, Chen WH, Parejo NA, Bhattacharjee AK, Cross AS
- Issue date: 2005 Dec 15